Section 6 of 6
References
198 sources
- Adler et al. (2025) (opens in a new tab)
- Agarwal et al. (2021) (opens in a new tab)
- Alnylam press release, ZENITH first patient dosed (2025) (opens in a new tab)
- AstraZeneca BAXFENDY prescribing information (2026) (opens in a new tab)
- AstraZeneca press release, baxdrostat NDA acceptance (2025) (opens in a new tab)
- AstraZeneca press release, Baxfendy EU CHMP opinion (2026) (opens in a new tab)
- AstraZeneca press release, BAXFENDY US approval (2026) (opens in a new tab)
- Azizi et al. (2021) (opens in a new tab)
- Azizi et al. (2023) (opens in a new tab)
- Azizi et al. (2026) (opens in a new tab)
- Baker (2026) (opens in a new tab)
- Bakris et al. (2024a) (opens in a new tab)
- Bakris et al. (2024b) (opens in a new tab)
- Beaney (2025) (opens in a new tab)
- Beyhaghi and Viera (2019) (opens in a new tab)
- Blood Pressure Lowering Treatment Trialists' Collaboration (2021) (opens in a new tab)
- Blumenthal et al. (2021) (opens in a new tab)
- Boehringer Ingelheim press release, EASi-KIDNEY update (2026) (opens in a new tab)
- Brown et al. (2020) (opens in a new tab)
- Bryant et al. (2023) (opens in a new tab)
- Burgos et al. (2025) (opens in a new tab)
- Calhoun et al. (2002) (opens in a new tab)
- Carey et al. (2018) (opens in a new tab)
- Carey et al. (2019) (opens in a new tab)
- Carris and Smith (2015) (opens in a new tab)
- Carris et al. (2016) (opens in a new tab)
- CDC About High Blood Pressure (2026) (opens in a new tab)
- CDC High Blood Pressure Facts (2026) (opens in a new tab)
- Chang et al. (2019) (opens in a new tab)
- ClinicalTrials.gov NCT02953132 (opens in a new tab)
- ClinicalTrials.gov NCT05001945 (opens in a new tab)
- ClinicalTrials.gov NCT05001945 results (opens in a new tab)
- ClinicalTrials.gov NCT05769608 (opens in a new tab)
- ClinicalTrials.gov NCT05968430 (opens in a new tab)
- ClinicalTrials.gov NCT06150924 (opens in a new tab)
- ClinicalTrials.gov NCT06150924 results (opens in a new tab)
- ClinicalTrials.gov NCT06153693 (opens in a new tab)
- ClinicalTrials.gov NCT06785454 (opens in a new tab)
- CMS 2027 Part C and D Star Ratings Technical Notes (2026) (opens in a new tab)
- CMS 2027 Star Ratings Measures and Weights (2026) (opens in a new tab)
- CMS decision memo, renal denervation for uncontrolled hypertension (2025) (opens in a new tab)
- CMS NADAC, amiloride 5 mg (2026) (opens in a new tab)
- CMS NADAC, BAXFENDY 2 mg (2026) (opens in a new tab)
- CMS NADAC, eplerenone 50 mg (2026) (opens in a new tab)
- CMS NADAC, spironolactone 25 mg (2026) (opens in a new tab)
- CMS National Coverage Determination 20.19, ambulatory blood pressure monitoring (2019) (opens in a new tab)
- Cohen et al. (2021) (opens in a new tab)
- Daugherty et al. (2012) (opens in a new tab)
- de la Sierra et al. (2011) (opens in a new tab)
- de la Sierra et al. (2024) (opens in a new tab)
- Deragon et al. (2025) (opens in a new tab)
- Desai et al. (2022) (opens in a new tab)
- Desai et al. (2025) (opens in a new tab)
- Dieleman et al. (2025) (opens in a new tab)
- Dixon et al. (2023) (opens in a new tab)
- Douma et al. (2008) (opens in a new tab)
- Durand et al. (2017) (opens in a new tab)
- Dwyer et al. (2026) (opens in a new tab)
- Earle et al. (2026) (opens in a new tab)
- Elbahloul et al. (2026) (opens in a new tab)
- Electronic Code of Federal Regulations, 21 CFR 312.21 (2026) (opens in a new tab)
- Eli Lilly ZEPBOUND prescribing information (2024) (opens in a new tab)
- Ettehad et al. (2016) (opens in a new tab)
- EU Clinical Trials Information System 2023-506425-12-00 (opens in a new tab)
- Fang et al. (2020) (opens in a new tab)
- FDA draft guidance, studies on a background of multiple antihypertensive drugs (2018) (opens in a new tab)
- FDA guidance, hypertension labeling for cardiovascular outcome claims (2011) (opens in a new tab)
- FDA guidance, ICH E1A extent of population exposure (1995) (opens in a new tab)
- FDA NDA 217686 supplement approval letter (2025) (opens in a new tab)
- FDA NDA 219878 approval letter (2026) (opens in a new tab)
- FDA PMA database, Paradise Ultrasound Renal Denervation System (2023) (opens in a new tab)
- FDA PMA database, Symplicity Spyral Renal Denervation System (2023) (opens in a new tab)
- FDA Table of Surrogate Endpoints (2026) (opens in a new tab)
- Fioretti et al. (2025) (opens in a new tab)
- Flack et al. (2024) (opens in a new tab)
- Flack et al. (2025) (opens in a new tab)
- Franklin et al. (2026) (opens in a new tab)
- Fryar et al. (2024) (opens in a new tab)
- Gaddam et al. (2008) (opens in a new tab)
- Geisler et al. (2012) (opens in a new tab)
- Gupta et al. (2017) (opens in a new tab)
- Henry et al. (2026) (opens in a new tab)
- ICER evidence report (2026) (opens in a new tab)
- ICER hypertension assessment page (2026) (opens in a new tab)
- ICER public comment folio (2026) (opens in a new tab)
- ICER public meeting slides (2026) (opens in a new tab)
- ICER response to public comments (2026) (opens in a new tab)
- Idorsia press release, aprocitentan commercialization partnership (2026) (opens in a new tab)
- Idorsia TRYVIO prescribing information (2026) (opens in a new tab)
- Jacob et al. (2017) (opens in a new tab)
- Jones et al. (2025) (opens in a new tab)
- Judge et al. (2025) (opens in a new tab)
- Kandzari et al. (2023) (opens in a new tab)
- Kandzari et al. (2024) (opens in a new tab)
- Kandzari et al. (2025) (opens in a new tab)
- Kazi et al. (2024) (opens in a new tab)
- Kirkland et al. (2018) (opens in a new tab)
- Krieger et al. (2018) (opens in a new tab)
- Laffin et al. (2023) (opens in a new tab)
- Laffin et al. (2025a) (opens in a new tab)
- Laffin et al. (2025b) (opens in a new tab)
- Lee et al. (2024) (opens in a new tab)
- Lee et al. (2025) (opens in a new tab)
- Lewington et al. (2002) (opens in a new tab)
- Lubitz et al. (2015) (opens in a new tab)
- MacLeod et al. (2022) (opens in a new tab)
- Mahfoud et al. (2022) (opens in a new tab)
- Malhotra et al. (2021) (opens in a new tab)
- Malhotra et al. (2024) (opens in a new tab)
- Mancia et al. (2023) (opens in a new tab)
- Martin et al. (2025) (opens in a new tab)
- McEvoy et al. (2024) (opens in a new tab)
- Mehra et al. (2026) (opens in a new tab)
- Million Hearts hypertension cascade (2023) (opens in a new tab)
- Mineralys Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
- Mineralys Therapeutics Form 10-K (2026) (opens in a new tab)
- Mineralys Therapeutics Form 10-Q (2026) (opens in a new tab)
- Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026) (opens in a new tab)
- Mineralys Therapeutics fourth quarter 2025 results announcement (2026) (opens in a new tab)
- Mineralys Therapeutics pipeline (opens in a new tab)
- Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025) (opens in a new tab)
- Mineralys Therapeutics press release, Advance-HTN NEJM publication (2025) (opens in a new tab)
- Mineralys Therapeutics press release, AHA Hypertension 2026 (2026) (opens in a new tab)
- Mineralys Therapeutics press release, ASN Kidney Week 2025 (2025) (opens in a new tab)
- Mineralys Therapeutics press release, board appointments (2026) (opens in a new tab)
- Mineralys Therapeutics press release, corporate update (2026) (opens in a new tab)
- Mineralys Therapeutics press release, ENDO 2026 (2026) (opens in a new tab)
- Mineralys Therapeutics press release, ESH 2025 Launch-HTN presentation (2025) (opens in a new tab)
- Mineralys Therapeutics press release, ESH 2026 (2026) (opens in a new tab)
- Mineralys Therapeutics press release, Explore-CKD publication (2026) (opens in a new tab)
- Mineralys Therapeutics press release, Explore-CKD topline results (2025) (opens in a new tab)
- Mineralys Therapeutics press release, Explore-OSA trial initiation (2025) (opens in a new tab)
- Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025) (opens in a new tab)
- Mineralys Therapeutics press release, Launch-HTN JAMA publication (2025) (opens in a new tab)
- Mineralys Therapeutics press release, Launch-HTN subgroup analyses (2025) (opens in a new tab)
- Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026) (opens in a new tab)
- Mineralys Therapeutics press release, Tanabe royalty repurchase (2026) (opens in a new tab)
- Mineralys Therapeutics press release, Target-HTN JAMA publication (2023) (opens in a new tab)
- Mineralys Therapeutics press release, Target-HTN topline results (2022) (opens in a new tab)
- Mineralys Therapeutics press release, Transform-HTN late-breaker selection (2026) (opens in a new tab)
- Mineralys Therapeutics press release, Transform-HTN results (2026) (opens in a new tab)
- Mineralys Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
- Mineralys Therapeutics third quarter 2025 results announcement (2025) (opens in a new tab)
- Mineralys Therapeutics third quarter 2026 earnings call transcript (2026) (opens in a new tab)
- Mineralys Therapeutics third quarter 2026 results announcement (2026) (opens in a new tab)
- Monticone et al. (2018) (opens in a new tab)
- Muntner et al. (2019) (opens in a new tab)
- Muntner et al. (2020) (opens in a new tab)
- NCD Risk Factor Collaboration (2021) (opens in a new tab)
- NCQA Blood Pressure Control for Patients With Hypertension measure (opens in a new tab)
- NCQA Controlling High Blood Pressure measure (opens in a new tab)
- Noubiap et al. (2019) (opens in a new tab)
- Owei et al. (2026) (opens in a new tab)
- Parati et al. (2021) (opens in a new tab)
- Pfizer ALDACTONE prescribing information (2025) (opens in a new tab)
- Pimenta et al. (2009) (opens in a new tab)
- Pollock (2025) (opens in a new tab)
- Queiroga et al. (2026) (opens in a new tab)
- Rabbitt et al. (2024) (opens in a new tab)
- Rasmussen et al. (2025) (opens in a new tab)
- Reddy et al. (2025) (opens in a new tab)
- S&P Global Market Intelligence (2026) (opens in a new tab)
- Sacks et al. (2001) (opens in a new tab)
- Saxena et al. (2025) (opens in a new tab)
- Saxena et al. (2026a) (opens in a new tab)
- Saxena et al. (2026b) (opens in a new tab)
- Saxena et al. supplementary appendix (2025) (opens in a new tab)
- Schlaich et al. (2022) (opens in a new tab)
- Shimbo et al. (2020) (opens in a new tab)
- Shimizu et al. (2024) (opens in a new tab)
- Sim et al. (2015) (opens in a new tab)
- Staplin et al. (2023) (opens in a new tab)
- Sullivan and Ghushchyan (2006) (opens in a new tab)
- Tajeu et al. (2016) (opens in a new tab)
- Taylor et al. (2025) (opens in a new tab)
- Teza et al. (2026) (opens in a new tab)
- Thomas et al. (2018) (opens in a new tab)
- Tortorici et al. (2024) (opens in a new tab)
- Trevisol et al. (2011) (opens in a new tab)
- Tsou et al. (2026) (opens in a new tab)
- Tuttle et al. (2024) (opens in a new tab)
- US Preventive Services Task Force (2021) (opens in a new tab)
- Velasco et al. (2015) (opens in a new tab)
- Vemulapalli et al. (2017) (opens in a new tab)
- Viatris INSPRA prescribing information (2025) (opens in a new tab)
- Victor et al. (2018) (opens in a new tab)
- Vogt et al. (2026) (opens in a new tab)
- Wallach et al. (2024) (opens in a new tab)
- Wang et al. (2024) (opens in a new tab)
- Weir et al. (2026) (opens in a new tab)
- WHO Drug Information (2022) (opens in a new tab)
- Williams et al. (2015) (opens in a new tab)
- Williams et al. (2018) (opens in a new tab)
- Woode et al. (2023) (opens in a new tab)
- World Health Organization hypertension fact sheet (2025) (opens in a new tab)
- Yousif et al. (2026) (opens in a new tab)
- Yusuf et al. (2026) (opens in a new tab)
- Zeijen et al. (2024) (opens in a new tab)